Introduction {#sec1}
============

Neuroblastoma, originating from the developing sympathetic nervous system, is the most common extracranial tumor of infancy and childhood. The median age at diagnosis is approximately 18 months \[[@B1]\]. It is a fatal solid cancer accounting for approximately 8--10% of all childhood malignancies \[[@B1]--[@B3]\] and contributes to approximately 10--15% of all cancer-related deaths in children \[[@B4]\]. Despite intensive multimodal treatments \[[@B5]\], 5-year event-free survival for high-risk (approximately 50% of all cases) neuroblastoma patients remains less than 50% \[[@B6],[@B7]\], and the 5-year survival rate for all neuroblastoma patients is approximately 50% \[[@B8]\]. Due to the rarity of neuroblastoma, strict associations are difficult to certify, and no particular environmental exposure has been involved in the development of this disease \[[@B1]\]. Thus, neuroblastoma remains a huge therapeutic challenge and global burden.

Previous genome-wide association studies (GWASs) of pancreatic ductal adenocarcinoma have identified a long intergenic non-coding RNA (lincRNA) *LINC00673* rs11655237 C\>T (also reported as G\>A elsewhere) polymorphism at 17q25.1 region to be significantly associated with the risk of pancreatic cancer \[[@B9]\]. It was the most significant polymorphism in the *LINC00673* \[[@B9]\]. Further studies have proven that the rs11655237 in exon 4 of *LINC00673* forms a target site for *miR-1231* binding, which weakens the tumor suppressing function of *LINC00673* in an allele-specific manner and thus endows pancreatic cancer with susceptibility \[[@B10]\]. Moreover, *LINC00673* has been identified to be associated with non-small-cell lung cancer (NSCLC) \[[@B11]--[@B13]\], gastric cancer \[[@B14]\], tongue squamous cell carcinoma \[[@B15]\], and breast cancer \[[@B16]\] consecutively. Together, these findings indicated that the *LINC00673* rs11655237 appears to be implicated in the development of broad-spectrum tumors and also involved in cell homeostasis maintenance. However, the association between neuroblastoma susceptibility and *LINC00673* rs11655237, is not yet reported.

To comprehensively evaluate and provide new insights into the impact of *LINC00673* rs11655237 C\>T polymorphism on neuroblastoma susceptibility, we performed a hospital-based case--control study using data from a Chinese Han population composed of 393 neuroblastoma cases and 812 age-, gender-, ethnicity-matched cancer-free controls.

Methods {#sec2}
=======

Study subjects {#sec2-1}
--------------

The subjects included were described in our previous studies \[[@B17]--[@B20]\]. A total of 393 histopathological cases of primary neuroblastoma and 812 cancer-free controls from Guangdong province (South China) and Henan province (North China) were recruited in the current study (Supplementary Table S1). Briefly, all the 393 cases were newly confirmed and histopathologically diagnosed as neuroblastoma patients without progressive disease and previous treatments before the collection of clinical classification. The cases were genetically unrelated Chinese Han children who received treatments at the Guangzhou Women and Children's Medical Center between February 2010 and March 2017, and at the First Affiliated Hospital of Zhengzhou University between August 2011 and April 2017. Age-, gender-, and ethnicity-matched controls were randomly recruited from children undergoing routine medical examination at the same center during the same period. The parents or guardians of the children provided written informed consent for the children's participation in the present study. The current study was approved by the Institutional Review Board of both centers and performed in accordance with the study protocol.

Genotyping {#sec2-2}
----------

DNA samples were extracted as previously described \[[@B21]\]. Briefly, DNA samples were diluted to a stock concentration of 10 ng/μl and added to 96-well plates. Genotyping for the *LINC00673* rs11655237 C\>T polymorphism was carried out in a 384-well plate using TaqMan Real-Time PCR method as described elsewhere \[[@B22]--[@B24]\]. For quality control and accuracy of genotyping results, approximately 10% of the samples were randomly selected and re-genotyped. The results were 100% concordant.

Statistical analysis {#sec2-3}
--------------------

Comparison of the differences in the demographic and genotypic information between neuroblastoma cases and controls was performed by chi-square test. Hardy--Weinberg equilibrium for controls was analyzed by goodness-of-fit chi-square test. To estimate the strength of association between rs11655237 C\>T polymorphism and neuroblastoma risk, unconditional univariate and multivariate logistic regression analyses were conducted and adjusted for age and gender, while odds ratios (ORs) and 95% confidence intervals (CIs) were used. Further stratified analysis was performed by age, gender, the International Neuroblastoma Staging System (INSS) clinical stages \[[@B25]\], and tumor sites. *P*-values \<0.05 were considered as statistically significant. All statistical analyses were two-sided and were calculated by SAS software (version 9.1; SAS Institute, Cary, NC, U.S.A.).

Results {#sec3}
=======

Demographic characteristics {#sec3-1}
---------------------------

The demographic characteristics of the included participants are summarized in Supplementary Table S1. No statistically significant differences were observed between neuroblastoma cases and controls regarding age (*P*=0.229, *P*=0.484, *P*=0.437) and gender (*P*=0.510, *P*=0.196, *P*=0.836) for Guangdong, Henan, and combined subjects, respectively. According to the INSS criteria, 69 (17.56%), 93 (23.66%), 68 (17.30%), 143 (36.39%), and 11 (2.80%) patients were diagnosed with clinical stages I, II, III, IV, and 4s disease, respectively. With respect to tumor sites, 153 (38.93%) neuroblastomas occurred in the adrenal glands, 87 (22.14%) in retroperitoneal regions, 109 (27.74%) in the mediastinum, and 36 (9.16%) in other regions.

*LINC00673* rs11655237 C\>T polymorphism and neuroblastoma susceptibility {#sec3-2}
-------------------------------------------------------------------------

The *LINC00673* rs11655237 genotype frequencies and their association with the susceptibility of neuroblastoma are presented in [Table 1](#T1){ref-type="table"}. A total of 391 of the included neuroblastoma cases and all controls (812) were successfully genotyped. We found that the rs11655237 T allele carriers (CT/TT compared with CC: adjusted OR = 1.31, 95% CI = 1.02--1.67, *P*=0.033; and T compared with C: adjusted OR = 1.29, 95% CI = 1.06--1.58, *P*=0.013), especially mutated-type homozygote carriers (TT compared with CC: adjusted OR = 1.80, 95% CI = 1.06--3.06, *P*=0.029), were significantly associated with an increased risk of neuroblastoma when compared with wild-type homozygote carriers.

###### Genotype distributions of *LINC00673* rs11655237 C\>T polymorphism and neuroblastoma susceptibility

  Genotype                        Cases (*n*=391)   Controls (*n*=812)   *P*[^1^](#T1TFN1){ref-type="table-fn"}   Crude OR (95% CI)       *P*         Adjusted OR (95% CI)[^2^](#T1TFN2){ref-type="table-fn"}   *P*[^2^](#T1TFN2){ref-type="table-fn"}
  ------------------------------- ----------------- -------------------- ---------------------------------------- ----------------------- ----------- --------------------------------------------------------- ----------------------------------------
  rs11655237 C\>T (HWE = 0.831)                                                                                                                                                                                 
  CC                              218 (55.75)       505 (62.19)                                                   1.00                                1.00                                                      
  CT                              146 (37.34)       272 (33.50)                                                   1.24 (0.96--1.61)       0.096       1.24 (0.96--1.60)                                         0.099
  TT                              27 (6.91)         35 (4.31)                                                     **1.79 (1.06--3.03)**   **0.031**   **1.80 (1.06--3.06)**                                     **0.029**
  Additive                                                               0.041                                    **1.29 (1.05--1.57)**   **0.014**   **1.29 (1.06--1.58)**                                     **0.013**
  Dominant                        173 (44.25)       307 (37.81)          0.033                                    **1.31 (1.02--1.67)**   **0.033**   **1.31 (1.02--1.67)**                                     **0.033**
  Recessive                       364 (93.09)       777 (95.69)          0.057                                    1.65 (0.98--2.76)       0.059       1.66 (0.99--2.79)                                         0.054
  C                               582 (74.42)       1282 (78.94)                                                  1.00                                1.00                                                      
  T                               200 (25.58)       342 (21.06)          0.013                                    **1.29 (1.06--1.57)**   **0.013**   **1.29 (1.06--1.58)**                                     **0.013**

*χ*^2^ test for genotype distributions between neuroblastoma cases and cancer-free controls.

Adjusted for age and gender. Results shown in bold if 95% CI excluded 1 or *P*\<0.05.

Stratified analysis {#sec3-3}
-------------------

Next, the included participants were stratified by age, gender, tumor sites, and INSS stages. We further estimated the effects of the variant genotype of the rs11655237 C\>T polymorphism on the neuroblastoma risk amongst the different strata ([Table 2](#T2){ref-type="table"}). We found that the rs11655237 CT/TT genotype carriers were significantly associated with an increased risk of a tumor originating in the adrenal gland (adjusted OR = 1.51, 95% CI = 1.06--2.14, *P*=0.021). Furthermore, we also found that the carriers of the CT/TT genotypes had a significantly increased risk of INSS clinical stage IV disease (adjusted OR = 1.60, 95% CI = 1.12--2.30, *P*=0.011) when compared with the carriers of the CC genotype.

###### Stratification analysis for the association between *LINC00673* rs11655237 C\>T polymorphism and neuroblastoma susceptibility for combined subjects

  Variables           rs11655237 (cases/controls)   Crude OR   *P*                     Adjusted OR[^1^](#T2TFN1){ref-type="table-fn"}   *P*[^1^](#T2TFN1){ref-type="table-fn"}   
  ------------------- ----------------------------- ---------- ----------------------- ------------------------------------------------ ---------------------------------------- -----------
  Age, months                                                                                                                                                                    
  ≤18                 72/194                        53/111     1.29 (0.84--1.97)       0.245                                            1.29 (0.84--1.97)                        0.246
  \>18                146/311                       120/196    1.30 (0.97--1.76)       0.083                                            1.30 (0.96--1.76)                        0.085
  Gender                                                                                                                                                                         
    Female            89/210                        79/132     1.41 (0.97--2.05)       0.070                                            1.41 (0.97--2.05)                        0.071
    Male              129/295                       94/175     1.23 (0.89--1.70)       0.215                                            1.23 (0.89--1.70)                        0.216
  Site of origin                                                                                                                                                                 
    Adrenal gland     80/505                        73/307     **1.50 (1.06--2.13)**   **0.022**                                        **1.51 (1.06--2.14)**                    **0.021**
    Retroperitoneal   49/505                        36/307     1.21 (0.77--1.90)       0.413                                            1.21 (0.77--1.91)                        0.402
    Mediastinum       65/505                        44/307     1.11 (0.74--1.68)       0.606                                            1.11 (0.74--1.67)                        0.618
    Others            22/505                        14/307     1.05 (0.53--2.08)       0.896                                            1.04 (0.53--2.07)                        0.904
  Clinical stages                                                                                                                                                                
    I + II + 4s       93/505                        69/307     1.22 (0.87--1.72)       0.254                                            1.21 (0.86--1.70)                        0.278
    III + IV          115/505                       95/307     1.36 (1.00--1.85)       0.050                                            1.35 (1.00--1.84)                        0.054
    III               43/505                        25/307     0.96 (0.57--1.60)       0.865                                            0.95 (0.57--1.59)                        0.854
    IV                72/505                        70/307     **1.60 (1.12--2.29)**   **0.010**                                        **1.60 (1.12--2.30)**                    **0.011**

Adjusted for age and gender. Results shown in bold if 95% CI excluded 1 or *P*\<0.05.

Discussion {#sec4}
==========

In this hospital-based case--control study, we evaluated the association of the GWAS-identified *LINC00673* rs11655237 C\>T polymorphism with neuroblastoma susceptibility in 393 patients and 812 cancer-free controls. Our results revealed that the rs11655237 T allele significantly increased the risk of neuroblastoma. In addition, stratified analysis showed that the rs11655237 C\>T polymorphism increased the risk of adrenal gland and clinical stage IV neuroblastoma. The results from the present study suggested that the rs11655237 T allele was positively associated with neuroblastoma and could confer neuroblastoma susceptibility.

Described as the largest subclass in the non-coding transcriptome in humans, lincRNAs are non-coding transcripts longer than 200 nts. In the past decade, the roles of lincRNAs in human disorders, including tumors, have attracted a lot of attention \[[@B26],[@B27]\]. lincRNAs are known to play vital regulatory roles in various processes \[[@B28]\], including but not limited to imprinting (*H19* \[[@B29]\] and *KCNQ1OT1* \[[@B30]\]), metastasis (*MALAT1* \[[@B31]\], *HOTAIR* \[[@B32]\], and *COLDAIR* \[[@B33]\]), X inactivation (*XIST* \[[@B34]\]), deregulation of the tumor suppressors \[[@B35]\], and pseudogene pairing (*PTENP1* \[[@B36]\]). Therefore, aberrant expression and polymorphisms within lincRNAs have been associated with susceptibility to a range of human diseases, including cancers. Cancer-associated lincRNAs, which demonstrate developmental and tissue-specific expression properties along with aberrant regulation in various malignancies, may indicate new approaches for the diagnosis and treatment of cancer. Systematic identification of the expression patterns and characterization of lincRNAs together with their associated proteins might contribute to the development of lincRNA-targetted therapies for tumors and various human diseases.

*LINC00673* is located at 17q24.3, which is a chromosome region recently documented to have a high frequency of loss of heterozygosity \[[@B37]\], and is associated with pancreatic cancer susceptibility in individuals of European ancestry \[[@B9]\]. Further studies have indicated that the *LINC00673* rs11655237 variant, a germline C\>T transition, can lead to a decrease in the level of *LINC00673* in cells, which may trigger SRC-ERK oncogenic signaling, while attenuating STAT1-dependent anti-oncogenic signaling. Consistent with these functional discoveries, researchers have observed significantly decreased pancreatic ductal adenocarcinoma susceptibility in the rs11655237 C allele carriers when compared with the rs116552337 T allele carriers \[[@B10],[@B38]\]. Intriguingly, *LINC00673* has been proven to be associated with susceptibility, progression, and outcome of other malignancies as either a tumor suppressor or promoter. Shi et al. \[[@B39]\] found that up-regulation of *LINC00673* can promote tumor proliferation through LSD1 interaction and repression of Neurocalcin δ in NSCLC, which implied *LINC00673* as an oncogene in NSCLC. For the first time, Ma et al. \[[@B40]\] showed that *LINC00673* promoted NSCLC metastasis by binding with EZH2 that resulted in epigenetic silencing of *HOXA5*. The latter is a tumor suppressor gene that inhibits NSCLC cell metastasis via regulating cytoskeletal remodeling. Lu et al. \[[@B11]\] found a similar situation in which *LINC00673* regulated NSCLC proliferation, invasion, migration, and even epithelial--mesenchymal transition by sponging *miR-150-5p*. A study by Abdul-Rahman et al. \[[@B16]\] showed that *LINC00673* levels were modulated by hormone signaling and inversely associated with breast cancer survival. Huang et al. \[[@B14]\] reported that *LINC00673* was significantly up-regulated in gastric cancer. *LINC00673* overexpression induced cell proliferation and invasion and inhibited cell apoptosis. Research conducted by Yu et al. \[[@B15]\] showed that *LINC00673* was highly expressed in a significant proportion of human tongue squamous cell carcinoma samples and associated with poor prognosis.

Taken together, these findings shed light on an important functional interaction between *LINC00673* and malignancies. Therefore, it would be interesting to examine the role of *LINC00673* in neuroblastoma. With such purpose, we conducted the current study in the Chinese Han population. The current study has several important strengths. To the best of our knowledge, this is the first investigation to validate the association of neuroblastoma susceptibility with GWAS-identified polymorphism within *LINC00673*. The identification of *LINC00673* as an antitumor factor in neuroblastoma was based on discoveries in GWASs in several tumors. Although our findings showed that the association between rs11655237 and neuroblastoma susceptibility were obtained in Chinese Han populations and are consistent with previous reports in other malignancies, further studies on this and other tumors in a different ethnic group would be beneficial. In addition, it has been suggested that rs11655237 might have a potential role in the regulation of gene expression via an enhancer, promoter, or silencer mechanism \[[@B9]\]. Therefore, further exploration of this issue should be addressed. Additionally, it would be intriguing to validate the effects of rs11655237 variation on the development of neuroblastoma using *in vivo* experimental settings.

Several limitations should be addressed in the present study. First, although it was the first study on the association between *LINC00673* and neuroblastoma, we included only 393 neuroblastoma cases and 812 cancer-free controls. The relative small sample size may limit the statistical power. Replication studies from other centers with a larger sample size are encouraged to confirm the association. Second, only one polymorphism of the newly identified *LINC00673* was investigated in the current study. More polymorphisms, especially the potentially functional polymorphisms not yet contained in previous GWASs, remain to be explored. Third, due to the design of the retrospective study, information bias and selection bias might be unavoidable. Because of the lack of information on dietary intake, living environmental factors, and parental exposures, only frequency matching of neuroblastoma cases and controls by age and gender could be used to reduce these biases. Fourth, *in vitro* and *in vivo* experiments should be performed to interrogate mechanism(s) underlying the association in the future. Finally, although recruited from two centers, including residents in Southern and Northern China, participants were all Han Chinese, so the results should be cautiously extrapolated to other ethnic groups.

In conclusion, our results verified that the *LINC00673* rs11655237 C\>T polymorphism was significantly associated with neuroblastoma susceptibility in the Chinese Han population, especially for children with neuroblastoma of the adrenal gland region and clinical stage IV. In the future, well-designed prospective studies with larger sample size including different ethnic populations, detailed information (including living environment, dietary intake, and parental exposures) and functional studies should be performed to strengthen our findings.
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